Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 5/20 | 0.56 |
| ▸ | GPR4 | P46093 | 2/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21850808 | 0.86 | KCNJ1 (0.55) | KCNJ1NSD2KDRRETSIGMAR1 | |
| SCHEMBL21850904 | 0.86 | KCNJ1 (0.46) | KCNJ1GPR4NSD2RETPARP1 | |
| SCHEMBL21850916 | 0.83 | KCNJ1 (0.43) | KCNJ1NSD2KDRRETSIGMAR1 | |
| SCHEMBL21850933 | 0.81 | KCNJ1 (0.45) | KCNJ1NSD2KDRRETPARP1 | |
| SCHEMBL21851187 | 0.81 | KCNJ1 (0.42) | KCNJ1NSD2KDRSIGMAR1CXCR4 | |
| SCHEMBL21850936 | 0.79 | KCNJ1 (0.41) | KCNJ1NSD2KDRSIGMAR1CXCR4 | |
| SCHEMBL21851188 | 0.78 | KCNJ1 (0.40) | KCNJ1NSD2KDRRETSIGMAR1 | |
| SCHEMBL12842019 | 0.78 | KDR (0.42) | NSD2KDRPARP1SIGMAR1CXCR4 | |
| SCHEMBL24135334 | 0.76 | KDR (0.40) | KCNJ1NSD2KDRSIGMAR1CXCR4 | |
| SCHEMBL21851189 | 0.75 | KDR (0.39) | KCNJ1NSD2KDRSIGMAR1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3929194-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | Bristol-Myers Squibb Company (US) | 2021-12-29 | — | — | EP | disclosed |
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | KCNJ1 562/4885GPR4 688/4885NSD2 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.